What did @mariahhopkins_ actually say?
She made two connected claims: first, that rotating your injection site can change both your results and your side effects on a GLP-1. Second, and more specifically, that when someone hits a weight loss stall, switching injection sites can be "the one thing that can change their whole experience." She acknowledged individual variation but framed site rotation as a practical lever people can pull when progress stops.
To her credit, she kept it practical and grounded. She named the three most common sites, abdomen, arm, and thigh, which aligns with manufacturer labeling for semaglutide and tirzepatide. She did not claim this is a cure, a dose change, or a guaranteed fix. That matters, because a lot of GLP-1 content on TikTok makes far bolder and less defensible claims.
Does the science back this up?
Partially. The pharmacokinetics data here is real, but it does not cleanly support the idea that site rotation breaks a stall. What the research actually shows is that absorption rates differ meaningfully by site, and that difference could plausibly affect drug exposure.
A study by Heise et al. (2014, Diabetes, Obesity and Metabolism) examining subcutaneous insulin absorption found that abdominal injection produces faster absorption than thigh injection in many patients. While that work focused on insulin rather than GLP-1 agonists, semaglutide's own prescribing information acknowledges that injection site can influence pharmacokinetics. A pharmacokinetic analysis of subcutaneous semaglutide (Marbury et al., 2017, Diabetes Therapy) found no clinically significant difference in overall bioavailability across abdomen, thigh, and upper arm, though variability existed between individuals. So the honest answer is: absorption differences are real but modest, and there is no controlled trial showing site rotation specifically breaks a plateau.
What did they get wrong (or right)?
The claim that site rotation affects side effects has some plausibility. Injection site reactions, localized nausea cues, and tissue sensitivity are all documented. Novo Nordisk's prescribing information for Ozempic and Wegovy explicitly recommends rotating sites to reduce local reactions. That part is correct and worth saying out loud.
Where she overreaches is framing site rotation as something that can break a stall. Weight loss plateaus on GLP-1 medications are multifactorial. Dose adequacy, dietary adherence, sleep, hormonal factors, and medication duration all interact. There is no peer-reviewed evidence that changing your injection site from abdomen to thigh restarts weight loss. The mechanism she implies, that different absorption unlocks better results, is speculative. It is not wrong enough to be dangerous, but it is not backed up the way she presents it.
The "everyone responds differently" caveat is appropriate and keeps this from being reckless. But it does not fully offset the confidence with which she frames site rotation as a stall-breaker.
What should you actually know?
If you are on a GLP-1 and hitting a plateau, injection site is probably not the variable that matters most. Plateaus are a normal physiological response to sustained caloric deficit. The body adapts. Research by Müller et al. (2018, Obesity Reviews) documented that metabolic adaptation during weight loss is real and not simply a matter of non-adherence.
That said, rotating injection sites is still recommended practice for a different reason: it prevents lipohypertrophy, the buildup of fatty tissue at overused injection sites, which can genuinely impair absorption over time. Repeatedly injecting the same spot can create a depot effect that reduces drug uptake. So rotating sites is good practice, just not primarily because it will restart your weight loss.
If you are stalling on a GLP-1, the conversation to have is with your prescriber about dose optimization, duration of therapy, and lifestyle factors. Not TikTok.